E7389
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Oct 1, 2011 → Dec 1, 2013
NCT ID
NCT01432886About E7389
E7389 is a phase 1 stage product being developed by Eisai for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01432886. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01432886 | Phase 1 | Completed |
| NCT00413192 | Phase 2 | Completed |
| NCT00326950 | Phase 1 | Completed |
| NCT00278993 | Phase 2 | Completed |
| NCT00246090 | Phase 2 | Completed |
| NCT00097721 | Phase 2 | Completed |
| NCT00069264 | Phase 1 | Completed |
| NCT00069277 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer